Abstract
Objective: To characterize the local adult drug-refractory epilepsy population and determine the efficacy and tolerability of clobazam in this group.
Background: Drug-refractory epilepsy occurs in approximately 30% of epilepsy patients and is notoriously difficult to treat. After failure of two anti-epileptic drugs (AEDs), only 3% of patients will become seizure-free with additional seizures medications. Clobazam is a promising long-acting benzodiazepine which was FDA-approved for use in Lennox-Gastaut syndrome in 2011.
Design/Methods: This was a single center retrospective chart review performed at the Hospital of the University of Pennsylvania. Subjects were >18 years old with drug-refractory epilepsy who were prescribed clobazam between 2010 and 2017. Patients were followed by the Penn Epilepsy Center with outpatient clinic visits both prior to and at least 1 month after initiation of clobazam. Data was collected on baseline demographics and epilepsy severity, as well as seizure frequency after reaching maximum tolerable dose, time to discontinuation, and adverse side effects. Primary outcome measures were rate of >50% seizure reduction and seizure freedom rate.
Results: 417 patients met study criteria. Prior to clobazam, patients were on an average of 2.4 active AEDs and 81.2% had seizures at least once a month. Post-intervention, 50.3% of patients experienced a >50% reduction in seizure frequency and 19.9% achieved seizure freedom, with no statistically significant difference between epilepsy types. 51% of patients experienced at least 1 side effect, most commonly lethargy/fatigue (30.7%) and mood changes (10.8%). A total of 143 (34.2%) patients discontinued clobazam, with the majority (55%) citing adverse effects as the reason for discontinuation.
Conclusions: Clobazam is effective as an adjunctive therapy for adult drug-refractory epilepsy. Rates of seizure reduction and seizure freedom were higher than what has been historically reported for other AEDs. Adverse side effects were common and limited tolerability in a minority of patients.
Disclosure: Dr. Levinson has nothing to disclose. Dr. Jamil has nothing to disclose. Dr. Khankhanian has nothing to disclose. Dr. Hill has nothing to disclose. Dr. Davis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB and UpToDate. Dr. Davis has received research support from Eisai Inc.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg